Cargando…

Advances in the management of craniopharyngioma

Craniopharyngioma is a curable benign tumor, but owing to its intimate relationship to critical structures in the central brain—such as the optic apparatus, pituitary, hypothalamus, intracranial vasculature, brain stem, and temporal lobes—its management introduces the risk of long-term treatment mor...

Descripción completa

Detalles Bibliográficos
Autores principales: O'steen, Lillie, Indelicato, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182675/
https://www.ncbi.nlm.nih.gov/pubmed/30363774
http://dx.doi.org/10.12688/f1000research.15834.1
_version_ 1783362621339074560
author O'steen, Lillie
Indelicato, Daniel J.
author_facet O'steen, Lillie
Indelicato, Daniel J.
author_sort O'steen, Lillie
collection PubMed
description Craniopharyngioma is a curable benign tumor, but owing to its intimate relationship to critical structures in the central brain—such as the optic apparatus, pituitary, hypothalamus, intracranial vasculature, brain stem, and temporal lobes—its management introduces the risk of long-term treatment morbidity. Today, the most common treatment approach is conservative subtotal resection followed by radiotherapy, and the goal is to limit long-term toxicity. Many recent advances in the treatment of craniopharyngioma are attributable to improved surgical techniques and radiotherapy technologies.
format Online
Article
Text
id pubmed-6182675
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-61826752018-10-23 Advances in the management of craniopharyngioma O'steen, Lillie Indelicato, Daniel J. F1000Res Review Craniopharyngioma is a curable benign tumor, but owing to its intimate relationship to critical structures in the central brain—such as the optic apparatus, pituitary, hypothalamus, intracranial vasculature, brain stem, and temporal lobes—its management introduces the risk of long-term treatment morbidity. Today, the most common treatment approach is conservative subtotal resection followed by radiotherapy, and the goal is to limit long-term toxicity. Many recent advances in the treatment of craniopharyngioma are attributable to improved surgical techniques and radiotherapy technologies. F1000 Research Limited 2018-10-11 /pmc/articles/PMC6182675/ /pubmed/30363774 http://dx.doi.org/10.12688/f1000research.15834.1 Text en Copyright: © 2018 O'steen L and Indelicato DJ http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
O'steen, Lillie
Indelicato, Daniel J.
Advances in the management of craniopharyngioma
title Advances in the management of craniopharyngioma
title_full Advances in the management of craniopharyngioma
title_fullStr Advances in the management of craniopharyngioma
title_full_unstemmed Advances in the management of craniopharyngioma
title_short Advances in the management of craniopharyngioma
title_sort advances in the management of craniopharyngioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182675/
https://www.ncbi.nlm.nih.gov/pubmed/30363774
http://dx.doi.org/10.12688/f1000research.15834.1
work_keys_str_mv AT osteenlillie advancesinthemanagementofcraniopharyngioma
AT indelicatodanielj advancesinthemanagementofcraniopharyngioma